Research map: Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression

Back to the article

Papers in this map

  1. A method for estimating the probability of adverse drug reactions · C. A. Naranjo · 1981 · 11882 citations · Cited by this paper
  2. Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies · 2026 · Related
  3. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression · Augustus John Rush · 2003 · 3951 citations · Cited by this paper
  4. Journal of Clinical Psychopharmacology Updates · 2026 · Related
  5. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation · Roger S. McIntyre · 2021 · 724 citations · Cited by this paper
  6. Vortioxetine Related Hypertriglyceridemia in a Young Male · 2026 · Related
  7. Side-effects associated with ketamine use in depression: a systematic review · Brooke L Short · 2017 · 567 citations · Cited by this paper
  8. Sugarless Candy in Treatment-Resistant Clozapine-Induced Sialorrhea · 2026 · Related
  9. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: A report of 3 cases · Ingeborg M. Noppers · 2011 · 160 citations · Cited by this paper
  10. Safety of Adjunct Low-Dose Methylphenidate Extended-Release for Cognitive Deficits in Stable Schizophrenia · 2026 · Related
  11. Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study · Naim Zaki · 2023 · 131 citations · Cited by this paper
  12. Menorrhagia Associated With Extended-Release Methylphenidate in an Adult Woman · 2026 · Related
  13. Trends in drug use among electronic dance music party attendees in New York City, 2016–2019 · Joseph J. Palamar · 2020 · 89 citations · Cited by this paper
  14. Hypnopompic Hallucinations · 2026 · Related
  15. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study · Meera M. Dhodapkar · 2022 · 81 citations · Cited by this paper
  16. Reading the Signal: What Psychedelic Trials in Depression Still Can’t Tell Us · 2026 · Related
  17. Liver Injury Is Common Among Chronic Abusers of Ketamine · Grace Lai‐Hung Wong · 2014 · 79 citations · Cited by this paper
  18. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression · Balwinder Singh · 2023 · 67 citations · Cited by this paper
  19. The Rapidly Shifting Ketamine Landscape in the US · Samuel T. Wilkinson · 2024 · 42 citations · Cited by this paper
  20. Ketamine‐Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient With COVID‐19 · Sally A.I. Knooihuizen · 2020 · 35 citations · Cited by this paper
  21. Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health records · Prakash M. Adekkanattu · 2022 · 32 citations · Cited by this paper
  22. Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval · Gerard Sanacora · 2025 · 31 citations · Cited by this paper
  23. The Association Between Thyroid Stimulating Hormone and Depression · Rakesh Kumar · 2023 · 28 citations · Cited by this paper
  24. Ketamine and Esketamine for Depression in Daily Practice · Balwinder Singh · 2024 · 17 citations · Cited by this paper
  25. Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression · Ana Jelovac · 2025 · 17 citations · Cited by this paper
  26. Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression · Liliana Patarroyo-Rodríguez · 2024 · 15 citations · Cited by this paper
  27. Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis · Angela T.H. Kwan · 2025 · 13 citations · Cited by this paper
  28. Secondary Sclerosing Cholangitis After SARS-CoV2: ICU Ketamine Use or Virus-Specific Biliary Tropism and Injury in the Context of Biliary Ischemia in Critically Ill Patients? · Alessandra Bartoli · 2023 · 10 citations · Cited by this paper
  29. Utility and limitations of the FDA adverse events reporting system public dashboard for safety analyses: a case study with vesicular monoamine transporter 2 inhibitors · Roger S. McIntyre · 2025 · 9 citations · Cited by this paper
  30. Substantial Elevation of Liver Enzymes During Ketamine Infusion: A Case Report · Xiaoying Zhu · 2020 · 7 citations · Cited by this paper
  31. Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine · Balwinder Singh · 2025 · 7 citations · Cited by this paper
  32. Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression · Stefanie Cavalcanti · 2025 · 4 citations · Cited by this paper
  33. Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression · Liliana Patarroyo-Rodríguez · 2025 · 3 citations · Cited by this paper
  34. S4399 Ketamine-Induced Liver Injury (KILI) From Recreational Use: A Rare Phenomenon · Nicole M. Anastasio · 2024 · 2 citations · Cited by this paper
  35. Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression. · Liliana Patarroyo-Rodríguez · 2025 · 1 citation · Cited by this paper
  36. Evidence-Based Pharmacotherapies for Major Depressive Disorder: A Clinical Update · Matheus G. Marques · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)